TIDMABC
RNS Number : 1418A
ABCAM Plc
02 October 2009
?
+---------------------------------------+--------------------------------+
| For immediate release | 2 October2009 |
+---------------------------------------+--------------------------------+
ABCAM PLC
("Abcam" or "the Company")
Annual Report & Accounts
Abcam plc (AIM: ABC), the rapidly growing bioscience company that markets
antibodies via its own online catalogue, announces that its Annual Report and
Accounts for the year ended 30 June 2009 has been posted to shareholders and is
available at the Company's investor relations website, www.abcamplc.com.
For further information please contact:
Abcam + 44 (0) 1223
696000
Jonathan Milner, Chief Executive Officer
Jeff Iliffe, Chief Financial Officer
www.abcam.com
Numis Securities + 44 (0) 20 7260 1000
Michael Meade / Nick Westlake - Nominated Adviser
James Black - Corporate Broking
Buchanan Communications + 44 (0) 20 7466 5000
Mark Court / Stasa Filiplic
Notes for editors
About Abcam plc
Abcam is a producer and distributor of research-grade antibodies headquartered
in Cambridge, United Kingdom, with offices in Cambridge, Massachusetts, USA and
Tokyo, Japan. Abcam was admitted to AIM in November 2005 and trades under the
ticker symbol ABC. The Company produces and distributes its own and third-party
produced antibodies to academic and commercial users throughout the world.
Product ordering is available through the Company's website www.abcam.com, where
customers are also able to access up-to-date and detailed technical product data
sheets. All the antibodies are sold under the Abcam brand name and the Company's
vision is to build the world's largest online resource of high-quality and
commercially viable antibodies. Abcam now has an online catalogue of over 55,000
products, most of which are antibodies, from over 250 suppliers and employs 237
staff in its three operating companies.
About antibodies
Antibodies are proteins produced by white blood cells in response to the
introduction of a foreign body known as an antigen. Antibodies, which have a
wide variety of uses in research, diagnostics and therapeutics, are used by
bioscientists in research into disease and into the human genome, where they are
used to mark and identify specific cells and other living matter. The number of
human antibodies of use in research is potentially greater than one million.
This information is provided by RNS
The company news service from the London Stock Exchange
END
ACSKLLBBKBBEFBD
|